Screener
Rigel Pharmaceuticals RIGL Single reportable segment — Other segment items
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Commercial related expenses | 7,040 | 5,339 |
| Outside clinical trial related expenses | 6,927 | 4,371 |
| Cost of product sales | 4,606 | 4,409 |
| Consultants and third-party services | 4,006 | 3,409 |
| Other segment items | 3,352 | 3,494 |
| Interest expense, net | 228 | 1,262 |
| Provision for income taxes | 3,003 | 65 |
| Segment income | $8,654 | $11,446 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's single reportable segment — other segment items?
- Rigel Pharmaceuticals (RIGL) reported single reportable segment — other segment items of $3.35M in Q1 2026.
- What does single reportable segment — other segment items mean?
- Encompasses miscellaneous operating costs or income items that do not fall into primary expense categories. Tracking these items helps identify non-recurring or secondary operational impacts on segment performance.
Ask your AI about Rigel Pharmaceuticals's single reportable segment — other segment items.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude